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Abstract
Recently, we demonstrated that D1 agonists can cause functionally selective effects when the
endpoints of receptor internalization and adenylate cyclase activation are compared. The present
study was designed to probe the phenomenon of functional selectivity at the D1 receptor further by
testing the hypothesis that structurally dissimilar agonists with efficacies at these endpoints that equal
or exceed those of dopamine would differ in ability to influence receptor fate after internalization, a
functional endpoint largely unexplored for the D1 receptor. We selected two novel agonists of
therapeutic interest that meet these criteria (the isochroman A-77636, and the isoquinoline
dinapsoline), and compared the fates of the D1 receptor after internalization in response to these two
compounds with that of dopamine. We found that dopamine caused the receptor to be rapidly recycled
to the cell surface within 1 h of removal. Conversely, A-77636 caused the receptor to be retained
intracellularly up to 48 h after agonist removal. Most surprisingly, the D1 receptor recovered to the
cell surface 48 h after removal of dinapsoline. Taken together, these data indicate that these agonists
target the D1 receptor to different intracellular trafficking pathways, demonstrating that the
phenomenon of functional selectivity at the D1 receptor is operative for cellular events that are
temporally downstream of immediate receptor activation. We hypothesize that these differential
effects result from interactions of the synthetic ligands with aspects of the D1 receptor that are distal
from the ligand binding domain.
Introduction
The dopamine receptors are a superfamily of heptahelical G protein-coupled receptors
(GPCRs) that have historically been partitioned into ”D1-like” and “D2-like” subfamilies
(Kebabian and Calne, 1979; Garau et al., 1978). The dopamine D1 receptor is a member of the
“D1-like” subfamily, and couples to adenylate cyclase through stimulatory G proteins Gs and
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Golf (Herve et al., 1993). The early steps in the regulation of the D1 receptor following the
binding of dopamine have been addressed in model cell lines. After the binding of dopamine
to the D1 receptor, receptor phosphorylation is complete within minutes (Gardner et al.
2001). This can be mediated by GRKs (Gardner et al., 2001; Tiberi et al., 1996) and/or protein
kinase A (PKA) (Mason et al., 2002). Both types of kinases may facilitate D1 desensitization,
and the contribution of each to the overall extent of receptor phosphorylation and
desensitization is probably highly dependant on the cell line being studied. Receptor
phosphorylation allows arrestin to bind to the third intracellular loop of the receptor (Kim et
al., 2004) leading to D1 receptor internalization. Arrestin is not trafficked into the cell with the
receptor, thus the D1 receptor is considered a “Class A” GPCR (Oakley et al., 2000). Following
dopamine-induced internalization, the D1 receptor is rapidly recycled back to the cell surface
(Vickery and von Zastrow, 1999; Vargas and von Zastrow, 2004). Recent studies indicate that
a signal sequence within the proximal C-terminal region of the receptor mediates this process
(Vargas and von Zastrow, 2004).
The effects of D1 agonists other than dopamine itself on regulatory events downstream of
receptor activation are not well characterized. Besides heuristic interest in these questions,
several of the D1 agonists that have been tested as antiparkinson agents in human and non-
human primates caused a very rapid tolerance evidenced as an almost complete loss of response
within a day or so (Asin and Wirtshafter, 1993; Kebabian et al., 1992; Lin et al., 1996; DeNinno
et al., 1991a; Johnson et al., 1992). Thus, such molecular events may be important in
understanding the cellular mechanisms that contribute to the development of this therapeutic
tolerance. Previously, we have observed that desensitization of adenylate cyclase responsivity
and receptor down-regulation are highly dependent upon the agonist used, but largely
independent of adenylate cyclase activity and agonist affinity in a stably transfected C6 glioma
cell line (Lewis et al., 1998). Recently, we explored the relationship between agonist structure,
receptor affinity, and efficacy of receptor internalization and adenylate cyclase activation in
greater depth by constructing an HEK cell line stably transfected with a hemaglutinin-tagged
human D1 receptor and comparing these endpoints in 13 agonists from three different structural
families. We found that D1 agonists exhibit functional selectivity at these early endpoints
following receptor activation that are apparently independent of agonist structure or binding
affinity (Ryman-Rasmussen et al., 2005).
These results suggested the major hypothesis tested herein, that D1 agonists are functionally
selective in regulating receptor function at the endpoint of intracellular trafficking of the D1
receptor, an endpoint that temporally lies downstream of adenylate cyclase activation and
internalization, events more immediate of receptor activation. We selected two agonists of
therapeutic interest, A-77636 and dinapsoline (DNS), for comparison with dopamine at this
endpoint. Both of these synthetic ligands have efficacies of internalization and adenylate
cyclase activation comparable to that of dopamine in the HA-hD1 HEK cell line (Ryman-
Rasmussen et al., 2005). The isochroman A-77636 elicits profound and rapid in vivo tolerance
occurring within approximately 24 h, preventing its use in Parkinson’s disease therapy (Lin et
al., 1996). Conversely, DNS does not cause such tolerance in a rat model of Parkinson’s disease
(Gulwadi et al., 2001). The mechanisms of tolerance are unknown, but presumably result from
cellular adaptations that lie temporally downstream of receptor internalization and adenylate
cyclase activation.. The current data demonstrate that although these agonists cause functional
changes identical to dopamine immediately following receptor binding, with time they modify
D1 receptor trafficking, and thus show a novel pattern of functional selectivity.
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Methods
Materials
Dopamine and A-77636 [(−)-(1R,3S)-3-adamantyl-1-(aminomethyl)-3,4-dihydro-5,6-
dihydroxy-1H-2-benzopyran hydrochloride)] were purchased from RBI/Sigma-Aldrich (St.
Louis, MO). Dinapsoline (8,9-dihydroxy-2,3,7, 11b-tetrahydro-1H-naph[1,2,3-de]
isoquinoline) and [3H] SCH23390 were synthesized according to published procedures (Ghosh
et al., 1996; Wyrick et al., 1986). All other reagents and materials were from Sigma Chemical
Company (St. Louis, MO), unless otherwise stated.
HA-hD1 HEK model cell line
The HA-hD1 HEK cell line was constructed as described previously (Ryman-Rasmussen et
al., 2005). Cells were maintained in DMEM-H, 10% FBS, 100 U/mL penicillin, 100 μg/mL
streptomycin, and 0.6 mg/mL geneticin at 37ºC and 5% CO2. Assay plates were coated with
4 μg/mL human fibronectin (Enzyme Research Laboratories Inc., South Bend, IN) at 37º C for
1 h or overnight, followed by addition of polylysine to 0.2 mg/mL for an additional 30 min to
prevent cell loss. Coating medium was aspirated and cells were immediately plated at a density
of 500–1000 cells per mm2.
Radioreceptor assays
HA-hD1 receptor expression level and affinity for dopamine, A-77636, and DNS were
determined by saturation binding and competition assays. Membrane homogenates from HA-
hD1 HEK cells were prepared as previously described (Lewis et al., 1998). Receptor density
and affinity of SCH23390 were measured by incubation of membrane homogenates in 0 to 2
nM [3H]SCH23390 in 50 mM HEPES, 4 mM MgCl2, 0.01% ascorbic acid, pH 7.4 for 15 min
at 37ºC. Yohimbine and propranolol (50 nM) were included to block endogenous adrenergic
receptors. Non-specific binding was determined by parallel incubations with 1 μM SCH23390.
Radioreceptor assays were done using either a Molecular Dynamics/Skatron harvester and
LKB 1209 RackBeta counter, or a Packard 96 Filtermate Harvester and TopCount Counter,
using appropriate glass fiber filters and scintillation fluid. The total protein concentration of
membrane preparations used in the saturation binding assays was determined by use of the
BCATM assay according to manufacturer’s instructions (Pierce, Rockford, IL). Affinity of
dopamine, A-77636, and DNS for the HA-hD1 receptor was determined by competition
(10−10 to 10−4 M) versus 0.3 nM [3H]SCH23390 in the presence of 50 nM propranolol and
yohimbine.
Adenylate cyclase functional potency and efficacy
Adenylate cyclase activation by dopamine, A-77636, and DNS was measured in whole HA-
hD1 HEK cells as previously described (Ryman-Rasmussen et al., 2005). Triplicate wells in
24 well plates were untreated or incubated with increasing concentrations of dopamine,
A-77636, or DNS in the presence of 500 μM IBMX at 37ºC for 15 min. Duplicate wells at the
highest concentration of agonist included the D1 receptor-selective antagonist, 50 μM
SCH23390, as a negative control. All wells contained 50 nM (S)-propranolol and yohimbine
to antagonize endogenous β-adrenergic receptors. The reaction was quenched with 0.1 N HCl,
and cAMP was quantified by a modified radioimmunoassay based on a previously published
method (Harper and Brooker, 1975).
Internalization assays
Internalization time-course assays were performed as previously described (Ryman-
Rasmussen et al., 2005). Briefly, 24-well plates of 1 d post-confluent HA-hD1 HEK cells were
adapted to treatment medium (L15 medium, 20 mM HEPES, 0.01% ascorbic acid pH 7.4) for
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1 h. One plate per treatment time point was used. Each plate contained control wells for no
drug (N=6), drug plus antagonist (N=2), and drug alone (N=4 per drug). Dopamine, A77636,
or DNS were added to cells a final concentration of 10 μM. For wells containing drug plus
antagonist, the final antagonist concentration (SCH23390 or butaclamol) was 50 μM. (S)-
propranolol and yohimbine were included in all wells at a final concentration of 50 nM to block
endogenous adrenergic receptors. Plates were incubated for 0 to 120 min in a 37ºC water bath,
rapidly cooled on ice, and fixed in 4% paraformaldehyde buffered with 0.1N sodium phosphate
prior to analysis for cell surface receptors by RIA vs. the HA-epitope. Internalization dose-
response assays were performed by treating HA-hD1 HEK cells with increasing concentrations
(10−10 to 10−3 M) of dopamine, A-77636, or DNS at 37ºC for 1 h in the presence of 50 nM -
(S)-propranolol and yohimbine in (N=4). All assays also contained control wells for no agonist
(N=6) and 10 μM agonist plus 50 μM of the antagonist, SCH23390 (N=2 per drug). At the end
of the incubation period, cells were fixed, and processed for a cell surface RIA of HA-hD1
using a primary antibody for the HA epitope as previously described (Ryman-Rasmussen et
al., 2005). All data were expressed as a percentage of untreated controls.
Assays for cell surface receptor recovery
Twenty-four well plates of 1 d post-confluent HA-hD1 HEK cells were adapted to treatment
medium (DMEM-H medium, 20 mM HEPES, 0.01% ascorbic acid pH 7.4) for 1 h. One plate
per treatment time point was used. Each plate contained control wells for No drug (N=6), and
drug and antagonist (N=2 per drug) in addition to drug treatment wells (N=4 per drug).
Dopamine, A-77636, or DNS were added to a final concentration of 10 μM. For wells
containing drug and antagonist, the final antagonist concentration (SCH23390 or butaclamol)
was 50 μM. (S)(−)propranolol and yohimbine were included in all wells at a final concentration
of 50 nM to block endogenous adrenergic receptors. Plates were incubated for 1 h at 37ºC and
5% CO2. Drug treatment medium was then aspirated, and cells were rinsed once with sterile
PBS prior to incubation in treatment medium without drug from 0 to 48 h. Cells were then
rapidly cooled on ice, and fixed in 4% paraformaldehyde buffered with 0.1N sodium phosphate
prior to analysis for cell surface receptors by RIA for the HA epitope as previously described
(Ryman-Rasmussen et al., 2005). Protein synthesis inhibition studies with 5 μM actinomycin
D (Calbiochem) were performed similarly, with the antibiotic added to the medium after
agonist removal.
Biotinylation studies
A modification of a previously published procedure was followed (Pan et al., 2003). EZ-Link
Sulfo-NHS-SS-BiotinTM (Pierce, Rockford IL) was freshly dissolved at 4–5 mg/mL in 20 mM
sodium phosphate buffer with 120 mM NaCl, pH 8.0 (at 4ºC). Twelve well plates of 1 d post-
confluent HA-hD1 HEK cells were washed twice with cold PBS, and biotinylated with 0.5 mL
of reagent for 60 min on ice. The reaction was quenched by addition of 1% BSA and 10 mM
glycine in sodium phosphate/NaCl for 10 min. The biotinylated cells were rinsed twice with
cold PBS, and adapted for 1 h at 37ºC in L15 medium with 20 mM HEPES, 0.01% ascorbic
acid, pH 7.4. Dopamine was added to the drug treatment wells to a final concentration of 10
μM, with propranolol and yohimbine present at 50 nM each. Plates were incubated for 1 h at
37ºC. Cells then were washed twice in cold PBS, and biotinylated cell surface receptors were
cleaved by two rounds of incubation in fresh 150 mM reduced glutathione (GSH)/150 mM
NaCl pH 8.8–8.9 (at 0ºC) on ice for 15 min. Cells were rinsed twice with cold PBS, and drug
free medium added, after which they either were placed on ice (0 hr) or incubated an additional
1 h at 37ºC. At the end of the incubation, cells were returned to ice. Cells were washed twice
in cold PBS, and another two rounds of incubation in fresh 150 mM GSH/150 mM NaCl pH
8.8–8.9 (at 0ºC) were performed in wells assaying for recycled, biotinylated receptor. Cells
were lysed in 1 mL 10 mM HEPES, 2 mM EDTA, 0.5% Triton X-100, 0.1% SDS pH 7.4 with
0.5 mM PMSF, passed through a 26G needle, and incubated an additional 1h at 4ºC to solubilize
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receptors. Samples were centrifuged at 14,000g for 15 min. A 20 μl aliquot of the supernatant
was saved for determination of protein concentration, and 900 μl of the supernatant was
transferred to new 1.5 mL tubes containing 75 μL of ImmunoPure Immobilized Avidin (Pierce
Biochemical, Rockford IL). Binding to the avidin resin proceeded for 2 h on a rotating platform
at 4ºC. Avidin resin was washed twice with lysis buffer and resuspended in 70 μL of Laemlli
buffer. Based on protein content prior to resin binding, approximately 35 μl of each sample
was separated on a 4–12% denaturing polyacrylamide gel (Novex/Invitrogen), and blotted onto
a PVDF membrane. Samples were blotted to a primary HA.11 antibody (Covance, Inc, from
mouse raw ascites) at a 1000-fold dilution followed by detection with a secondary rabbit anti-
mouse antibody conjugated to horseradish peroxidase (BioRad). Bands were revealed by
chemiluminescent detection (ECLTMSystem, Amersham) and exposure to film (BioFilm,
Denville Scientific).
Determination of protein synthesis inhibition with [35S]-methionine
Twenty-four well plates were washed twice with sterile PBS. Then [35S]-methionine (1000
μCi/ml Amersham) was added to DMEM-H medium buffered with 20 mM HEPES and 0.01%
ascorbic acid pH 7.4, with and without 5 μM actinomycin D to a final concentration of 2 nM,
and incubated 24 or 48 h. Replicate wells for cell viability assays without [35S]-methionine
were also included in the experiment. At the end of the incubation period, cells were washed
twice with PBS. [35S]-methionine-labeled cells were lysed in 10 mM HEPES, 2 mM EDTA,
0.5% Triton X-100, 0.1% SDS, pH 7.4, and an aliquot counted on a beta counter (RackBeta).
Similarly-treated, non-radioactive cells were washed twice with PBS. MTT (thiazolyl blue)
was added to DMEM at 250μg/mL, and applied to cells for 15 min. Cells were rinsed twice
with PBS. DMSO was added to the wells to solubilize the precipitate and plates were placed
on a rocker platform for 15 min. Aliquots from the wells were read in a spectrophotometer
(BioRad) at 595 nm (Twentyman and Luscombe, 1987). The amount of [35S]-methionine in
actinomycin D-treated and untreated wells was normalized to the absorbance of MTT in
similarly treated wells. Data were expressed as a percentage of samples untreated with
actinomycin D.
Metabolic labeling of HA-hD1 with [35S]-methionine
Six-well plates of 85% confluent HA-hD1 HEK cells were starved for 6–8 h in methionine-
free DMEM medium (Specialty Media/Cell and Molecular Technologies, Inc.) containing 100
U/mL penicillin, 100 μg/mL streptomycin, and 0.6 mg/mL geneticin. “Starving medium”
containing 10% FBS, 10 μM cold methionine, and 0.02–0.04μM [35S]-methionine
(Amersham-Pharmacia) were added to the cells for 18 h. After labeling, cells were washed
three times with sterile PBS, and equilibrated in DMEM-H medium, 20 mM HEPES, 0.01%
ascorbic acid, pH 7.4, containing 0.6 mM cold methionine. Drug treatment and recovery studies
were done as described earlier, except methionine levels in the medium were maintained at 0.6
mM (normally 0.2 mM). At the end of the recovery studies, cells were rinsed twice with cold
PBS, lysed in RIPA buffer with 0.5 mM PMSF containing 100 U/mL DNAse and 1 mg/mL
RNAse (Boehringer Mannheim), and scraped into 1.5 mL tubes. Tubes were incubated at 4ºC
on a rotary platform for 1 h to solubilize receptors and digest nucleic acids. Tubes were
centrifuged at 14,000 g, and 800 μl was transferred to new 1.5 mL tubes. A 20 μL aliquot was
saved for determination of protein content. 35[S]-Met-HA-hD1 was immunoprecipitated by a
procedure similar to one published previously (Tiberi et al., 1996). Twenty μl of Protein G-
Sepharose (Amersham Pharmacia) was added to each tube, and the tubes were incubated at
4ºC on a rotary platform for 1 h to pre-clear the supernatant. The supernatant again was
transferred to a new tube, a 100-fold dilution of the HA.11 primary antibody was added to each
tube, and samples were incubated for 2 h at 4ºC on a rotary platform. Fifty μL of Protein G-
Sepharose was added to each tube, and incubation continued for 1 h. Immunoprecipitated
samples were washed three times with RIPA, and the immunoprecipitate resuspended in 25
Ryman-Rasmussen et al. Page 5
Neuropharmacology. Author manuscript; available in PMC 2008 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
μL Laemlli buffer. The same amount of total protein (ca. 25 μL) was loaded on 4–12%
denaturing polyacrylamide gel (Novex/Invitrogen), and the gel run according to the
manufacturer’s instructions. The gel was fixed for 1 h in a 20% methanol, 10% acetic acid
solution, and dried on a gel drier (BioRad). Dried gels were exposed to PhosphorImager plates
(Molecular Dynamics/Amersham Biosciences, Piscataway, NJ) and exposed for 2–4 days.
Images were scanned on a Typhoon Imager (Molecular Dynamics), and band densities
quantified with ImageQuantTM (Amersham Biosciences) software based on average number
of pixels per band.
Confocal microscopy
HA-hD1 HEK cells were grown to 50% confluency on glass coverslips coated with fibronectin
and polylysine in 24-well plates. Cells were treated in duplicate with either dopamine, A77636,
or DNS (all at 10 μM) for 1 h in the presence of 50 nM (S)-propranolol and yohimbine, as
described above. Cells were rinsed with PBS, and returned to the incubator for assessment of
cell surface recovery at 1 h, 12 h and 48 h, as described above. At the end of the recovery assay,
cells were fixed in ice-cold, freshly made methanol-free 4% paraformaldehyde buffered in 0.1
N sodium phosphate (pH 7.4) on the bench for 30 min. Fixed cells were rinsed twice with PBS,
and permeabilized with 0.3% Triton X-100 in DMEM/50 mM HEPES/10% FBS for 30 min
on ice to allow antibody access to receptors on the cellular interior. Permeabilized cells were
blocked with 5% BSA in DMEM/50 mM HEPES/10% FBS for 30 min, and incubated with a
1:1,000 dilution of the HA.11 primary antibody (from mouse raw ascites, Covance, Inc.) as
described above. Detection was by 1 h incubation with a secondary rat anti-mouse antibody
conjugated to the Cy3 fluorophore (Jackson Immunolabs). Coverslips were rinsed with PBS,
and wet-mounted with DAPI-containing VectashieldTM medium (Vector Labs, Inc.). Slides
were scanned in 0.6 μm steps on an upright Leica SP2 confocal microscope with a 63 X (oil)
Plan Apo objective (NA 1.4 to 0.6). The DAPI fluorophore was excited with a 351/364 nm
UV laser line and the cy3 fluorophore with a 568 nm krypton laser line. Detection was in
tunable channels optimized for the emission of these fluorophores, with no observable
fluorophore overlap. Images represent the cellular interior, approximately midway through the
thickness of the cells. Data are representative of three independent experiments conducted at
different times.
Molecular modeling
We predicted the three-dimensional structure of human dopamine D1 receptor using the
MembStruk method (Trabanino et al., 2004). We then used the HierDock ligand docking
method (Vaidehi et al., 2002) to locate the binding region for dopamine, for the two
stereoisomers of dinapsoline and for four diastereomers of A-77636. We then predicted the
details of the binding site for these ligands (allowing protein side chains to change and the
backbone to relax), and calculated their binding energies (details of the structure and binding
site to be published elsewhere).
Displacement radioreceptor assay
HEK 293 cells stably expressing the hD1-wild-type receptor were harvested to produce
membranes for use in receptor binding assays. 100 mM culture dishes containing the HEK
cells were washed with ice cold PBS 1X and then lysed for ~15 min. with 3 mL ice cold lysis
buffer (10mM Hepes, pH 7.4). Cells were scraped, transferred to centrifuge tubes and spun at
28,000 g for 20 min. Pellets were then transferred to a Wheaton Glass/Teflon homogenizer in
10 mM Hepes buffer, and homogenized five times. Homogenization and centrifugation was
repeated for a total of two times. The final pellet was resuspended in storage buffer (20 mM
Hepes, 250 mM sucrose, pH 7.4), aliquoted in 1 mL microcentrifuge tubes and snap-frozen.
Membrane aliquots were stored at −80 C until use.
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For use, membranes were thawed, washed, resuspended in assay buffer (50 mM HEPES/4 mM
MgCl2, pH 7.4), and then divided into four aliquots of 500 μL each. The following was added
to each aliquot at a final concentration of 10 μM: I) A77636; II) dinapsoline; III) dopamine;
and IV) Buffer only. All samples were incubated at 37°C for 15 min. Upon termination of the
incubation, each sample was washed twice by centrifugation at 5000 g for 5 min and
resuspended in buffer. Each aliquot was then resuspended in 5 mL of buffer containing
phenylmethanesulfonyl fluoride, and incubated for 60 min at 37°C. The samples were washed
once more by centrifugation and resuspended in assay buffer. Samples (250 μL) were then
tested for binding capacity (500 μL final assay volume) using 0.5 nM and 5 nM [3H]SCH23390
(i.e., 1*KD and 5*KD) to label D1 receptors. Half of the tubes also contained 1 μM unlabeled
SCH23390 to estimate non-specific binding. Binding was initiated by the addition of tissue to
the tubes, and after incubation for 15 min at 37°C, the reaction was terminated by filtering with
ice-cold buffer on a Packard Filtermate cell harvester (Packard Instruments, Downers Grove,
IL). Radioactivity was measured using a Packard TopCount Microplate Scintillation and
Luminescence Counter.
Data and statistical analysis
Affinity data were fit first to a sigmoidal model of variable slope. The data then were resolved
assuming a two-site model, to yield a KD(high) and KD(low) and percent of sites in each state.
K0.5 values were calculated from the IC50s using the bimolecular competitive model from
Cheng and Prusoff (1973). The data for adenylate cyclase potency were expressed as the
percentage of cAMP produced at the highest concentration of agonist used and the data for
internalization potency expressed as percentage cell surface receptors of untreated controls.
The data for both of these functional endpoints were fit to a sigmoidal dose-response curve.
All of the analyses of these dose-response data were performed using Prism Ver. 3 or 4
(GraphPad, Inc, San Diego CA). An ANOVA with a post-hoc Tukey test was used to compare
means for all internalization and recovery experiments. Significance was set at p<0.05. All
statistical testing was done using Systat Version 6 software (Systat Software Inc., Point
Richmond CA).
Results
Radioreceptor assays
Saturation binding with the D1-selective antagonist, [3H] SCH23390, in membrane
homogenates indicated that the assay expression level of HA-hD1 in this cell line is
approximately 4 ± 1 pmol/mg membrane protein with a KD of 2.4 ± 0.8 nM (Figure 1, Panel
A and Table 1). Competition assays of dopamine, A-77636, and DNS versus [3H] SCH23390
were performed to determine the affinities of these compounds for the HA-hD1 receptor (Figure
1, Panel B and Table 1). Dopamine and DNS best fit a two-site binding model, whereas
A-77636 best fit a one-site model. These values are in agreement with results previously
obtained in this model cell line (Ryman-Rasmussen et al., 2005) and those published results
in rat striatal homogenates and in vitro expression systems (Ghosh et al., 1996;Lewis et al.,
1998).
Internalization time course of HA-hD1
We characterized the temporal course of receptor internalization in response to these three
agonists. Internalization for all three agonists is best described as a first-order process with a
half-life of less than 10 min that reaches a steady-state by 30 min that is stable to at least 2 h
(Figure 2A).
A one-hour agonist treatment time was chosen for subsequent studies because it is midway
through the observed steady state (see Figure 2A). At this time, steady state levels of cell surface
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HA-hD1 differ significantly between agonists (Figure 2B). An average of 78 ± 6% of cell
surface HA-hD1 remain after treatment with dopamine, compared to 69 ± 3% after treatment
with DNS, and 62 ± 3% after treatment with A-77636 (see legend of Figure 2 for statistics).
The loss of cell surface HA-hD1 in response to all three agonists was blocked with the D1
selective antagonist, SCH 23390, consistent with the hypothesis that this process is mediated
through activation of the D1 receptor.
Adenylate cyclase and internalization functional potency and efficacy
Adenylate cyclase functional potency and efficacy were then assessed for all three agonists in
whole cells (Figure 3, Panel A). Dopamine had an EC50 of 91 ± 47 nM versus 5.7 ± 1.8 nM
for A-77636 and 10 ± 3.0 nM for DNS. A-77636 and DNS also had full intrinsic activity relative
to dopamine, in agreement with previous work (DeNinno et al., 1991b;Lewis et al.,
1998;Ghosh et al., 1996;Ryman-Rasmussen et al., 2005). Additionally, D1-mediated activation
of adenylate cyclase for all three agonists was completely blocked by the D1-selective
antagonist SCH23390 (data not shown).
The rank order of efficacy in eliciting an internalization response was A-77636 > DNS >
dopamine (Figure 2, Panel B). The functional potencies of internalization also were determined
for each agonist (Figure 3, Panel B). Dopamine had an EC50 of 600 ± 200 nM versus 80 ± 10
nM for A-77636 and 200 ± 100 nM for DNS.
Rapid recycling of HA-hD1 to the cell surface after treatment with dopamine
HA-hD1 HEK cells were treated with 10 μM dopamine, A-77636, or DNS for 1 h, rinsed with
PBS, and incubated in drug-free medium for 0 to 48 h. As shown in Figure 4, 1 h after removal
of dopamine, HA-hD1 was significantly recovered to the cell surface (p<0.001) to levels that
are undistinguishable from control values. Conversely, no recovery of cell surface HA-hD1
was observed at this time point after removal of either A-77636 or DNS. In fact, a significant
decrease in cell surface HA-hD1 was observed for both agonists (A-77636: p<0.001; DNS:
p<0.05).
We hypothesized that recovery of the HA-hD1 receptor in response to dopamine was the result
of receptor recycling, based on previous reports (Vickery and von Zastrow, 1999; Vargas and
von Zastrow, 2004). We therefore used a cell impermeable, cleavable biotinylation reagent to
label all cell surface receptors prior to agonist treatment. This assay allows cleavage of non-
internalized receptors by glutathione (GSH) after agonist treatment, so that only the fate of
internalized receptors is tracked. Internalized receptors were isolated rapidly by binding to
avidin-Sepharose, and the HA-hD1 receptor identified by Western blotting with an HA.11
antibody. Thus, the fate of internalized HA-hD1 was tracked unequivocally, and other
mechanisms (e.g., new receptor biosynthesis or export of cytosolic receptors to the surface)
ruled out (Figure 5). Efficient labeling of cell surface HA-hD1 was achieved (Lane 2) with low
background (Lane 1), and the signal in the absence of dopamine (Lane 2) was mostly eliminated
by cleavage with GSH (Lane 3). One h after treatment with 10 μM DA and cleavage of cell
surface HA-hD1 with GSH, there was internalization of HA-hD1 (Lane 4). One h after removal
of DA from the drug treatment medium, a band corresponding to HA-hD1 was present on the
surface and interior of the cell (Lane 6). After cleavage with GSH, the remaining receptors on
the interior of the cell (Lane 7) were significantly reduced relative to the total present (Lane
6), but were slightly increased compared to control levels (Lane 5). Thus, the difference in
band density between Lanes 6 and 7 can be mainly attributed to recycled HA-hD1. These data
indicate that the majority of HA-hD1 was recycled back to the cell surface within 1 h of removal
of DA from the culture medium. Unfortunately, this method could not be applied to assess the
fate of internalized HA-hD1 in response to A77636 and DNS, possibly as a result of hydrolysis
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of the disulfide bond in the cleavable biotin label in cellular compartments or from prolonged
(up to 48 h) incubation times (data not shown).
Delayed responses of HA-hD1 following removal of A-77636 or DNS
The differences observed 1 h after agonist removal from the culture medium raised questions
about drug-specific differences over time. Thus, cell surface HA-hD1 receptors were examined
at later time points after removal of these agonists. Significant decreases in cell surface HA-
hD1 were observed at 24, 36, and 48 h after removal of A-77636, whereas for DNS, there was
a small but significant increase in cell surface HA-hD1 by 48 h (Figure 6, Panel A). Comparison
of the 0 and 48 h time points (Figure 6, Panel B) shows that 48 h after removal of A-77636,
cell surface HA-hD1 decreased from 65 ± 2% to 46 ± 3% (p<0.001 ). Conversely, there was a
significant increase in cell surface HA-hD1 after removal of DNS, from 73 ± 2% to 82 ± 5%
(p<0.05). Thus, after DNS-treatment, cell surface receptors were still significantly decreased
relative to untreated controls at 48 h (p<0.001), but were significantly greater than in cells
treated with A-77636 (p<0.001).
Delayed recovery of HA-hD1 is independent of new protein synthesis
This most logical explanation for an increase in cell surface HA-hD1 density 48 h after removal
of DNS from the medium is new receptor biosynthesis. Cell surface biotinylation studies could
have ruled this out unequivocally, but could not be used due to hydrolysis of the label during
the extended length of the experiment. Therefore, we utilized protein synthesis inhibition to
determine if protein synthesis was required for receptor recovery 48 h after DNS treatment.
Cycloheximide was first tried, but was too cytotoxic in this cell line at efficacious
concentrations (data not shown). We therefore used Actinomycin D. The maximum tolerated
concentration of actinomycin D in this cell line for 48 h was 5 μM (data not shown). Inhibition
of protein synthesis was determined quantitatively by metabolic labeling studies with [35S]-
methionine. Actinomycin D treatment caused noticeable differences in the confluency of these
cells after 48 h of treatment, compared to untreated controls (data not shown), and so
determination of the degree of inhibition of protein synthesis required normalization to the
number of viable cells. An MTT cell viability assay was used for this purpose. Based on
comparison of incorporated [35S]-methionine in actinomycin D-treated and untreated controls,
new protein synthesis was inhibited 31 ± 1.2% within 24 h and 45 ± 2.2% within 48 h by
actinomycin D (Figure 7 Panel A). Replacement of the cell culture medium at 24 h with a fresh
actinomycin D did not significantly decrease the incorporation of [35S]-methionine at 48 h
(data not shown). As shown in Figure 7, Panel B, inclusion of actinomycin D in the medium
after agonist removal causes no significant change in the cell surface HA-hD1 response
resulting from treatment with dopamine, A-77636, or DNS, indicating that new protein
synthesis did not mediate receptor recovery to the cell surface after removal of DNS from the
culture medium.
Metabolically labeled D1 receptors after 48 h
Although protein synthesis inhibition by Actinomycin D was significant, it was not complete,
and could not completely rule out new receptor biosynthesis as the mechanism by which cell
surface HA-hD1 density is recovered. It also could not rule out an alternative mechanism of
export of cytosolic receptors to the cell surface. We therefore pursued pulse-chase experiments
in which cellular proteins were “pulsed” with [35S]-methionine and “chased” with an excess
of cold methionine prior to HA-hD1 receptor internalization and recovery assays in response
to agonists. At the end of the recovery period, radiolabeled receptors were recovered by
immunoprecipitation. Thus, the same pool of cell surface HA-hD1 present at the time of agonist
exposure could be followed over 48 h. These experiments showed that the [35S]-met HA-
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hD1 present during agonist exposure was present 48 h after agonist removal. A similar result
was obtained for untreated controls (Figure 8, Panels A and B).
Visualization of receptor localization by confocal microscopy
The previous, quantitative assays provided valuable evidence of rapid HA-hD1 recovery to the
cell surface in response to dopamine, delayed recovery in response to DNS, and no recovery
in response to A77636. These quantitative data gave no indication of whether or not these
agonists might cause differential localization of the receptor within the cell. We therefore
visualized HA-hD1 receptor localization in permeabilized cells by confocal microscopy at
various time points after agonist removal from the culture medium (Figure 9). In the absence
of agonist, the HA-hD1 receptor was localized primarily to the cell membrane. After 1 h
treatment with 10 μM dopamine, the HA-hD1 receptor localizes to a large endosomal-like
structure outside the nucleus. This occurred with a concomitant decrease in cell surface receptor
staining. One h after dopamine was removed, HA-hD1 cell surface receptor density recovered
to levels similar to that observed in untreated controls and the large endosomal-like structure
was absent. Treatment of HA-hD1 HEK with 10 μM A-77636 or DNS clearly show that surface
receptors recover much slowly with DNS or not at all with A-77636. One h after A-77636
treatment, a pronounced loss in cell surface staining for HA-hD1 receptors was apparent and
internalized receptors were localized to numerous, large endosomal-like structures on the
interior of the cell. Cell surface HA-hD1 receptor density did not recover within the 48 h
observation period. One h after DNS treatment, the HA-hD1 receptor staining was evident in
numerous, fused endosomal-like structures. A large endosomal-like structure was well-defined
at 12 h and persisted at 24 h, at which time some cell surface HA-hD1 staining was observed
(data not shown). At 48 h, recovery of cell surface HA-hD1 staining was apparent and the large
endosomal-like structure was absent.
Molecular modeling of the D1 receptor
The in vitro data strongly suggested that agonist structure might be the determinate that affected
the differential trafficking of the D1 receptor. To explore the molecular factors that make
A-77636 and dinapsoline traffic the D1 receptor so differently from each other and from
dopamine, we examined the differences in the D1 binding site of dopamine, dinapsoline and
A-77636. For all three ligands [S(+) dinapsoline, (1R,3S) A-77636, and dopamine] the
predicted binding site in the D1 receptor involves several common elements. These include
amino acids in TM3 [V100(3.29), D103(3.32), and I104(3.33)], in TM5 [S199(5.43), S202
(5.46), F203(5.47)], in TM6 [F288(6.51), L291(6.54), N292(6.55)], and in TM7; [F313(7.35),
V317(7.39)]. This model shows several predicted differences in the binding site for A-77636
and for dopamine. These arise from N97(3.26) on TM3; F156(4.58), V159(4.61) and W163
(4.65) on TM4; A195(5.39), V200(5.44) on TM5; L291(6.54) and L295(6.58) on TM6; and
F313(7.35) and V317(7.39) on TM7. These residues all have favorable van der Waals
interaction with A-77636 (~6 Kcal/mol more so than for dopamine). Predicted contributions
to differential binding of dinapsoline and dopamine arise from I104(3.33) on TM3, F156(4.58)
on TM4, V200(5.44) and F203(5.47) on TM5, and P287 on TM6, providing ~3 Kcal/mol better
interaction energy to the D1 receptor. Figure 10 shows that the adamantyl group of A-77636
protrudes from the extracellular domain of D1 receptor to interact with W163(4.65) on TM4.
Thus the accessory hydrophobic adamantyl group of A77636 may be stabilized by the
extracellular loops in a way that markedly decreases ligand dissociation.
Displacement results consistent with limited dissociation of A-77636 from the D1 receptor
It has been hypothesized that A-77636 dissociates slowly from the D1 receptor, but this based
solely on indirect evidence that there is continued accumulation of cAMP after apparent
removal of drug (Lin et al., 1996). To provide additional direct evidence for this hypothesis,
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we used the strategy of radioligand displacement. Either A-77636 (1 μM) or buffer (as vehicle)
was incubated with striatal membranes for 15 min, the membranes were diluted, allowed to
equilibrate, washed, and then assayed for available D1-like binding sites. As shown in Figure
12, membranes pretreated with A-77636 showed a dramatic reduction in the number of
available SCH23390 binding sites even after repeated washing and dilution. For the untreated
membranes, or those pretreated with DA or DNS, the data fit a one-site binding model with an
R2 >0.94 for each case. In addition, the KD for [3H]SCH23390 was essentially identical for
control membranes (0.51 ± 0.09 nM) versus ones pretreated with DNS (0.41 ± 0.07 nM) or
DA (0.29 ± 0.05 nM), but the estimated KD for the A77636 treated membranes had a 95%
confidence interval that included 0. These results are consistent with the hypothesis from the
model outlined in the previous section.
Discussion
Utilizing an HA-hD1 HEK cell line (Ryman-Rasmussen et al., 2005), we studied the
intracellular trafficking of the D1 receptor following binding of dopamine and two structurally
dissimilar agonists, A-77636 and DNS. These agonists were similarly efficacious to dopamine
in activating adenylate cyclase, and caused a similar time course of D1 receptor internalization.
Conversely, the synthetic agonists had quite different effects on events that were not temporally
proximal to initial receptor occupation. The current study investigated these interesting
differences in D1 receptor trafficking using a variety of endpoints that probed cell surface D1
receptor density in response to agonist activation.
We first characterized the time-course of internalization of the HA-hD1 receptor in response
to dopamine, A-77636, or DNS. In all cases, internalization was best described as a first-order
process that reached a steady-state by 30 min and was then constant until 2 h. Whereas DNS
was of similar efficacy to dopamine in causing internalization in this cell line, A-77636 caused
significantly greater internalization, essentially acting like a “super agonist” at this function,
but not at adenylate cyclase. The rank order of potency (A-77636 ≥ DNS ≫dopamine) was
similar at internalization and adenylate cyclase activation, although both A-77636 and DNS
had somewhat lower potency at the former. From this data, we established for all three agonists
that a 1 h treatment time at a concentration that gave high occupancy (10 μM) was sufficient
to achieve steady-state levels of D1 receptor internalization. This provided the basis for
assessing post-endocytic agonist effects on receptor trafficking.
The cell surface RIA data, in conjunction with confocal microscopy, showed that HA-hD1
receptor density was recovered on the cell surface 1 h after removal of dopamine, indicating
that the D1 receptor rapidly recycled in this cell line after binding dopamine. Alternative
explanations, such as export of cytosolic receptors to the cell surface or, less likely, protein
biosynthesis, were ruled out by the use of a cell impermeable, cleavable biotinylation reagent.
This demonstrated unequivocally that recovery of the receptor to the cell surface in response
to dopamine was a result of receptor recycling. These data were consistent with earlier studies
that showed that D1 receptor is recycled rapidly back to the surface of HEK cells after dopamine
removal (Vickery and von Zastrow, 1999; Vargas and von Zastrow, 2004).
Conversely, treatment with A-77636 had a very different effect on HA-hD1 receptor
localization. After a 1 h treatment with A-77636 and removal of free drug, neither cell surface
RIA, nor confocal microscopy, showed evidence of recovery to the cell surface in the next 48
h. The cell surface RIA data showed a significant decline in cell surface receptor number
between 24 and 48 h after removal of A-77636. This sustained loss of cell surface receptors
after the PBS wash and subsequent incubation in drug-free medium was probably due to
continued receptor internalization as a result of the very slow dissociation of A-77636 from
the receptor (Figure 12 and Lin et al., 1996). Further support for our hypothesis on the persistent
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receptor internalization came from pulse-chase studies with [35S]-methionine that
demonstrated that roughly half of the A-77636-treated HA-hD1 was still present 48 h after
agonist removal. Additionally, the confocal data demonstrated that A-77636 targets the
receptor to numerous endosomal-like structures within the cell after 1 h of agonist treatment,
structures that were still visible 48 h later. Taken together, these data indicate that the retained
receptor (likely complexed with agonist) is resistant to degradation. This result is unexpected,
since GPCRs that are not recycled are usually rapidly degraded. The persistence of the D1
receptor intracellularly after treatment with A-77636 may be explained by the unusual
resistance of the receptor to proteolysis (Vargas and von Zastrow, 2004). As an aside, our data
showing inability of A-77636 to dissociate from the D1 receptor in washed membranes rules
out receptor phosphorylation or other enzyme catalyzed events in the most proximal
mechanism involved in this unusual trafficking.
Another unexpected finding was observed with DNS. The cell surface RIA data indicates that
DNS caused very delayed recovery of cell surface HA-hD1 receptor density. This result was
supported by the confocal data that showed that DNS caused localization of the receptor to a
large endosomal-like structure after 1 h of treatment. Following removal of DNS from the
culture medium, this endosomal-like structure was still evident at 12 and 24 h, indicating that
the receptor was not degraded. Forty-eight h after DNS removal, this endosomal-like structure
was absent and receptor staining was recovered on the cell surface.
Such a delay between receptor internalization and recovery of D1 receptors after DNS treatment
is, to our knowledge, highly unusual for a recycled GPCR. Therefore, we tested the alternative
hypothesis that new protein biosynthesis was responsible for the delayed HA-hD1 receptor
recovery following DNS treatment. Use of actinomycin D resulted in 45% inhibition of protein
synthesis without marked effects on cell viability. The 24–48 h interval during which protein
synthesis inhibition occurred corresponded to the time during which recovery of HA-hD1
receptor density to the cell surface was seen after DNS removal. The actinomycin D, however,
had no effect on cell surface HA-hD1 recovery. These data were consistent with the hypothesis
that new protein biosynthesis was not the mechanism responsible for the cell surface recovery
of the HA-hD1 receptor following DNS removal. To provide additional evidence, we conducted
pulse-chase studies with [35S]-methionine to determine if the original pool of HA-hD1 present
prior to DNS treatment was still present 48 h later. These data demonstrated that roughly 50%
of the original receptors were indeed present at this time point. Taken together, these data
strongly indicated that the delay in recovery of the D1 receptor to the cell surface after treatment
with DNS resulted from receptor recycling. The metabolic labeling studies also indicated that
roughly half of the original pool of HA-hD1 receptor present prior to treatment with all agonists
was still present 48 h later, a result that was observed in both untreated cells and cells treated
for 1 h with dopamine, A-77636, or DNS. This result indicates that 1 h of exposure to these
agonists is not sufficient to accelerate or decelerate the rate of receptor turnover in this cell
line. Slow turnover of the receptor is expected under these experimental conditions because
serum and selective antibiotic are absent from the medium during this time.
The apparent ability of dopamine, A-77636, and DNS to cause differential effects in the
intracellular trafficking of the D1 receptor despite their very similar acute functional effects
raises two important questions: what structural features of the ligands are responsible for the
unique actions of the synthetic agonists, and what domains of the receptor are involved in this
transduction. One hypothesis that should be tested further is the relative role of ligand
dissociation on these trafficking changes. Dopamine, the smallest and most hydrophilic of these
agonists, is the one that causes most rapid receptor recycling, whereas A-77636 and DNS more
hydrophobic, and also are hypothesized to engage additional aspects of the receptor. Our data
(Figure 12), coupled with that of Lin et al. (1996), provide compelling evidence that A-77636
persists on the D1 receptor for long periods of time and cannot be removed by thorough washing
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of membranes or by competition with excesses of antagonist. Our docking studies of A77636
in the predicted structure of the D1 receptor (see Figure 10) support the suggestions from
previous experiments (Mottola et al., 1996; Grubbs et al., 2004; Ghosh et al., 1996; Mailman
et al., 1998) that the accessory hydrophobic adamantyl group of A77636 is stabilized by
residues near the extracellular domain sufficiently to eliminate dissociation. For example, we
predict that the adamantyl group in A-77636 ligand interacts with V159, W163 on TM4 and
L291, L295 on TM6, with these residues in the extracellular end of the TM regions contributing
6 Kcal/mol extra stabilization (i.e., enthalpic contributions but not entropic or temperature
dependent terms) to binding of A-77636, but none for dopamine. In our ligand docking
calculations, we scanned the entire receptor structure for locating the possible binding site(s)
of the ligands A-77636, dinapsoline, and dopamine. For dinapsoline and A-77636, apart from
the binding site between TMs 3, 4, 5 and 6 described above (shown in Figure 11, left), we
found a much weaker but perhaps significant secondary binding site for dopamine was in the
intracellular portion of the inter-helical regions of TM 3, 4, 5 and 6 (see Figure 11, right).
Although we have not characterized this site computationally, the observation suggests that
there could be an allosteric binding site that recognizes the endogenous agonist to play a role
in reformation of the receptor. This site might not be recognized by other agonists (such as
dinapsoline and A-77636], perhaps explaining the low degree of dissociation and its subsequent
effects on receptor recovery.
If further research confirms that slow dissociation of D1 ligands is a key initiating factor that
results in dramatically altered patterns of receptor trafficking, then the underlying mechanisms
would be of importance. Agonist dissociation may be necessary in order for the sorting
sequence in the proximal C-terminus of the D1 receptor to interact with the endosomal sorting
machinery that targets the receptor to a rapid recycling pathway (Vargas and von Zastrow,
2004). In addition, dissociation of the agonist may be required to mediate arrestin dissociation
from the receptor (or vice-versa). Arrestin is not trafficked into the cell with the D1 receptor
in response to dopamine (Zhang et al., 1999). Thus, in the case of dopamine, the D1 receptor
fits the profile of a “Class A” GPCR. “Class B” GPCRs, in contrast, are still associated with
arrestin when they are internalized and the cycling of this class of receptors is much slower
(Oakley et al., 2000). An inability of the agonist-receptor-arrestin complex to dissociate upon
internalization, possibly as a result of stabilization of the arrestin-receptor complex by a ligand
like A-77636 could thus be hypothesized to “convert” a Class A GPCR to a Class B GPCR.
The persistence of HA-hD1 intracellularly as a result of treatment with A-77636, or to a lesser
extent, DNS provides some evidence that this could happen. It would be ideal to be able to
measure the intracellular concentrations of ligand directly, but chemical methods are not
adequately sensitive, and would be confounded by trapped (non-specific) ligand. Moreover,
the current data show that post-treatment that includes washing and competition from
antagonists cannot remove the ligand even at short time intervals, let alone after the receptor
has been trafficked away from the cell surface.
In summary, this study shows that structurally dissimilar D1 agonists that are similar in terms
of their acute functional profile (e.g., adenylate cyclase) are functionally selective (Simmons,
2005; Mailman and Gay, 2004; Urban et al., 2006) in regard to long-term receptor trafficking.
These findings open the door to future mechanistic studies in three distinct areas. First, what
are the important ligand-receptor interactions that allow ligand-specific differentiation of long-
term trafficking for compounds that otherwise appear functionally similar. Second, what
intracellular mechanisms are involved in the unusual trafficking of such novel ligand-receptor
complexes. Finally, do the involved intracellular mechanisms provide a clue as to the reason
that A-77636 causes profound motor tolerance in vivo over a similar time course to that studied
here. Investigation into all three areas will help define the universality of this phenomenon and
its overall physiological importance.
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Non-standard abbreviations
cAMP  
cyclic AMP; adenosine 3′ 5′-cyclic monophosphate
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A-77636  
(1R,3S)-3-(1’adamantyl)-1-aminomethyl-3,4-dihydo-5,6-dihydroxy-1H-2-
benzopyran)
DA  
Dopamine
DNS  
dinapsoline; (8.9-dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]
isoquinoline)
GRK  
G protein-coupled receptor kinase
HEPES  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
RIA  
Radioimmunoassay
SCH23390  
7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
TMx  
Transmembrane spanning section X
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Figure 1. Characteristics of HA-hD1 receptor
(A). Saturation binding of [3H] SCH3390 to HA-hD1. Data in Figure were from one of three
independent experiments that had a KD=2.4 ± 0.8 nM; BMAX=4 ± 1 pmol HA-hD1/mg
membrane protein.
(B). Affinity of dopamine, A-77636, and DNS for the HA-hD1 receptor. Non-specific binding
was 17 ± 2.3%. Affinities are summarized in Table I.
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Figure 2. Time course for internalization of dopamine, A-77636, and DNS in HA-hD1 HEK cells
(A). HA-hD1 HEK cells were treated with 10 μM dopamine, A-77636, or DNS for 0 to 120
min in quadruplicate. Data are expressed as a percentage of vehicle-treated controls at all time
points, and represent the mean and standard errors of three independent experiments.
(B) Cell surface HA-hD1 remaining at steady state (1 h). HA-hD1 HEK cells were treated with
10 μM dopamine, A-77636, or DNS in quadruplicate for 1 h in the presence of 50 nM -(S)-
propranolol and yohimbine. A subset of samples also contained 50 μM SCH23390 in duplicate.
Data are expressed as a percentage of vehicle-treated controls at all time points and are the
means and standard errors of three to eight independent experiments. A two sample t-test was
used to compare samples treated with agonist in the presence and absence of SCH23390 (a:
p≤0.005). ANOVA followed by a post hoc Tukey test was used to determine significant
differences in loss of cell surface receptors after 1 h of treatment with dopamine, A-77636, or
DNS (b: p<0.001 compared to A-77636; c: p<0.03 compared to DNS; d: p=0.05 compared to
DNS).
Ryman-Rasmussen et al. Page 18
Neuropharmacology. Author manuscript; available in PMC 2008 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. Functional effects of the D1 agonists
(A). Adenylate cyclase functional potency in whole cells. HA-hD1 HEK cells were incubated
with increasing concentrations of dopamine, A-77636, and DNS in quadruplicate. Data are the
means and standard errors of four to five independent experiments: EC50 dopamine=91± 47
nM; EC50 A-77636=5.7± 1.8 nM; EC50 DNS=10 ± 3.0 nM. SCH23390 completely blocked
activation caused by all three agonists (data not shown).
(B). Functional potency of internalization. HA-hD1 HEK cells were treated with increasing
concentrations of dopamine, A-77636, or DNS for 1 h in the presence of 50 nM -(S)-propranolol
and yohimbine in quadruplicate. Data are expressed as a percentage of vehicle-treated controls
at all time points and were fitted to sigmoidal dose-response curves and EC50s determined by
using Prism software: Dopamine=600± 200 nM; A-77636=80 ± 10 nM; DNS=200 ± 100 nM.
Data are the means and standard errors of three to six independent experiments.
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Figure 4.
Recovery of cell surface HA-hD1 1 h after agonist removal. HA-hD1 HEK cells were treated
with 10 μM dopamine, A77636, or DNS for 1 h in quadruplicate. A cell surface RIA for the
HA tag was used to measure cell surface HA-hD1 1 h after agonist removal Data are expressed
as a percentage of vehicle-treated controls and are the means and standard errors of four to five
independent experiments. A one way ANOVA with a post-hoc Tukey test was used to compare
dopamine-treated cells at 0 and 1 h after dopamine removal (a, p<0.001) and to compare
dopamine-treated versus untreated controls at 1 h after agonist removal (b, p>0.05). A-77636
and DNS were also compared at 0 and 1 h after removal of these agonists (A-77636: c, p<0.001;
DNS: d, p<0.05).
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Figure 5.
Reversible biotinylation of cell surface HA-hD1. HA-hD1 HEK cells were biotinylated with a
cell impermeable, cleavable reagent. Biotinylated receptor was then tracked in response to DA
treatment and removal in duplicate as described in Experimental Procedures. Lane labels are
as follows: Background: background binding of non-biotinylated HA-hD1 to avidin resin;
Surface: total biotinylation of cell surface HA-hD1 in the absence of DA; Con: Cleave #1:
remaining cell surface HA-hD1 after GSH cleavage in the absence of DA (a control for
completeness of GSH cleavage); 1 h DA:Internal: internalized HA-hD1 after 1 h of DA
treatment and cleavage of cell surface HA-hD1 with GSH; Con: cleave #2: remaining cell
surface HA-hD1 after second GSH cleavage (control for completeness of second GSH
cleavage); Surface + Internal: total HA-hD1 (internalized and surface) after 1 h of DA treatment
followed by 1 h of DA removal; Internal: internalized HA-hD1 remaining after removal of cell
surface HA-hD1 by second GSH cleavage (i.e. HA-hD1 that was not recycled).
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Figure 6. Time effects of changes in cell surface receptors
(A). Time course of changes in cell surface HA-hD1 after removal of A77363 and DNS. Cell
surface RIA of HA-hD1 HEK cells treated with 10 μM A-77636 or DNS in quadruplicate for
1 h, rinsed with PBS and incubated in drug-free medium for 0–48 h. Data are expressed as the
percentage of vehicle-treated controls at all time points and are the means and standard errors
of four to five independent experiments. (*) p≤0.03, (**) p=0.08 compared to t=0.
(B) An ANOVA with a post-hoc Tukey test was used to compare A-77636-treated cells at 0
and 48 h after A-77636 removal (a, p<0.001) and to compare cells treated with DNS at 0 and
48 h after DNS removal (b, p<0.05). At 48 h, DNS-treated receptors are significantly decreased
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relative to untreated controls (c, p<0.001), but are significantly elevated compared to those
treated with A-77636 (d, p<0.001).
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Figure 7. Inhibition of protein synthesis by actinomycin D
(A). HA-hD1 HEK cells were labeled with [35S]-methionine in the presence or absence of 5
μM actinomycin D for 24 or 48 h in triplicate. Similar, unlabeled samples (without the
radiolabel) were run in parallel for quantification of viable cells by a spectrophotometric MTT
assay. Data were normalized to the absorbance of reduced MTT and are expressed as the
percentage of incorporation of [35S]-methionine in untreated controls. A two-tailed t-test was
used to compare the extent of label incorporation at 24 and 48 h (*) p=0.008.
(B) Actinomycin D does not alter the response of HA-hD1 to agonist treatment. Cell surface
RIA of HA-hD1 HEK cells treated with 10 μM dopamine, A-77636, or DNS for 1 h in
quadruplicate, rinsed, and incubated in drug-free medium in the presence or absence of 5 μM
actinomycin D for 48 h. Data were expressed as a percentage of vehicle-treated controls. A
one-way ANOVA with a post-hoc Tukey test was used to compare the effects of actinomycin
D treatment on receptor density for each agonist at 48 h after agonist removal (p>0.05).
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Figure 8. Pulse-chase labeling of HA-hD1 with [35S]-methionine
(A). HA-hD1 HEK cells were labeled with [35S]-methionine prior to treatment with agonist or
vehicle in duplicate for 1 h and incubation in agonist-free medium for 0 or 48 h. Data are
representative of three independent experiments.
(B). Graph of the pixel density in each band (above) with standard deviation (corrected for
background).
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Figure 9.
Visualization of HA-hD1 subcellular localization in response to agonist treatment and removal
by confocal microscopy. HA-hD1 staining [HA.11 primary antibody, cy3 secondary antibody
converted to grayscale) is localized primarily to the cell membrane in HA-hD1 HEK cells
untreated with agonist (top row at left),. The HA-hD1 receptor is localized intracellularly 1 h
after treatment with 10 μM agonist (middle row). After washing and incubation in drug-free
medium, HA-hD1 staining recovers to the cell surface 1 h after removal of dopamine (middle
row at left) and is evident at 48 h after removal of DNS (bottom row at right). No recovery of
cell surface HA-hD1 staining is observed in response to A-77636 (second and third row at
middle). DAPI staining for cell nuclei was removed to clearly show the receptor. Arrows
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indicate a large endosomal-like structure containing internalized HA-hD1. Data are
representative of three independent experiments performed in duplicate.
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Figure 10.
Predicted docking of dopamine, dinapsoline, and A-77636 to the D1 receptor located between
TM helices 3, 4, 5 and 6. The residues from the extracellular end of the TM regions are predicted
to be involved in binding of the synthetic ligands, but not dopamine. Extracellular domain is
at the top.
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Figure 11.
Panel A. Top view (from the extracellular end) of the location of the secondary binding site
for dinapsoline and A-77636 in human dopamine D1 receptor. The secondary binding site is
postulated as allosteric, and is located at the intracellular half of the TM barrel between helices
3, 4, 5 and 6. Panel B. Side view of the location of the binding site.
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Figure 12.
Inability of [3H]SCH23390 to displace A-77636 in membranes from HEK cells expressing
hD1 receptors. After preincubation with dopamine, dinapsoline, or A-77636, the membranes
were washed extensively as described in the Methods. Mini-saturation assays then were
performed using [3H]SCH23390 concentrations equal to 1*KD and 10*KD. There was almost
complete loss of binding caused by the pretreatment with A-77636, but not dinapsoline or
dopamine.
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Table 1
Summary of ligand binding affinity in HA-hD1 HEK cells.
Ligand K0.5 (nM) ηH KD(High) (nM) KD(Low) (nM) % High Affinity
SCH 23390 2.4 ± 0.8 1.0 NA NA NA
Dopamine 370 ± 1.2 0.34 ± 0.05 17 ± 0.30 2100 ± 38 46 ± 3
A77636 1.77 ± 0.01 1.27 ± 0.13 NA NA NA
Dinapsoline 26.8 ± 1.3 0.42 ± 0.07 1.40 ± 0.01 120 ± 4 42± 7
NA = not applicable
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